Antisense Inhibitor definition

Antisense Inhibitor means an oligonucleotide or analog thereof that inhibits protein synthesis at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective inhibition of gene expression.
Sample 1Sample 2Sample 3
Antisense Inhibitor means an Oligonucleotide that is designed to inhibit protein synthesis at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid by
Sample 1Sample 2
Antisense Inhibitor means an Oligonucleotide that is designed to inhibit protein synthesis at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid by base-paring. * Confidential Treatment Requested
Sample 1

Examples of Antisense Inhibitor in a sentence

  • Except as provided otherwise herein, ISIS will have the sole and exclusive right to file, prosecute, maintain, enforce and defend any Research Target Patent Rights and any ISIS Patents or Joint Patents filed on Inventions claiming an Antisense Inhibitor to a Research Target or a method of treatment using an antisense molecule that modulates a Research Target subject to a License to Research or License to Exploit hereunder, regardless of inventorship.

  • ATL further warrants and represents that, to the best of its knowledge as of the Amendment Date, if ISIS makes an Antisense Inhibitor to any of the Research Targets, it will not constitute an infringement of any Third Party rights and that ATL will indemnify ISIS, as set forth in Section 11.1 herein, should a subsequent determination be made that Third Party rights were infringed.

  • ATL further warrants and represents that, to the best of its knowledge as of the Effective Date, if ISIS makes an Antisense Inhibitor to any of the Research Targets, it will not constitute an infringement of any Third Party rights and that ATL will indemnify ISIS, as set forth in Section 11.1 herein, should a subsequent determination be made that Third Party rights were infringed.

  • If a License to Research or License to Exploit, other than any such license with respect to ATL 1102, VLA4 Compounds and Other VLA4 Compounds and VLA4 Products, is terminated for any reason, promptly upon any such termination, the parties will prepare a transition plan to ensure the seamless transition of any clinical studies and distribution and sales activities relating to any Antisense Inhibitor, Collaboration Compound, and/or Collaboration Compound Product from ATL to ISIS.

  • If Isis informs the JRC that it is unable to create an optimized Antisense Inhibitor to such Celera Gene Target and, as a result, will not be delivering Collaboration Data to the JRC for such Celera Gene Target, such Celera Gene Target will not be included in the Celera Gene Availability Pool.

  • ISIS 766720-CS2 titled “A Double Blind, Placebo- Controlled, Phase 2A Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS-GHR- LRX, An Antisense Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 Days for 16 Weeks in Patients with Acromegaly Being Treated with Long-acting Somatostatin Receptor Ligands (SRL)” (the “Protocol”), and Institution and Investigator possesse expertise in the conduct and performance of clinical studies.

  • Similarly, the parties understand that the discovery of a method of treating human disease by inhibiting a particular gene product, where ISIS’ Antisense Inhibitor data is used to support the claims of the Patent, may be a Joint Invention.

  • If ATL requests additional quantities of any such Antisense Inhibitor, the terms of supply will be mutually agreed upon by the parties in writing.

  • In addition, ATL will provide ISIS with any and all data relating to such Antisense Inhibitor, Collaboration Compound, Product using ISIS Standard Chemistry and/or to any ISIS Patent Rights relating to any Research Target that are in ATL’s possession or control.

  • A Phase 1 Dose-Escalation Study of Apatorsen (OGX- 427), an Antisense Inhibitor Targeting Heat Shock Protein 27 (Hsp27), in Patients with Castration Resistant Prostate Cancer and Other Advanced Cancers.

Related to Antisense Inhibitor

  • Biomarker means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention. Biomarkers include, but are not limited to, gene mutations or protein expression.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications, or derivatives thereof, but excluding single variable domains (heavy or light) of such antibodies.

  • Diagnostic Product means an assemblage of reagents, including but not limited to reagents packaged in the form of a kit, useful in performing a Licensed Service.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Receptor means enclosed spaces, conduits, protected groundwater sources, drinking and non-drinking water wells, surface water bodies, and public water systems which when impacted by chemicals of concern may result in exposure to humans and aquatic life, explosive conditions or other adverse effects on health, safety and the environment as specified in these rules.

  • Corrosion inhibitor means a substance capable of reducing the corrosivity of water toward metal plumbing materials, especially lead and copper, by forming a protective film on the interior surface of those materials.

  • Gene Therapy means the introduction of a nucleic acid sequence encoding a protein intended for or otherwise conferring therapeutic benefit into a person for therapeutic purposes (i) by in vivo introduction for incorporation into cells of such person, or (ii) by ex vivo introduction into cells for transfer into a person.

  • Bioassay means the determination of kinds, quantities or concentrations and, in some cases, the locations of radioactive material in the human body, whether by direct measurement, in vivo counting, or by analysis and evaluation of materials excreted or removed from the human body. For purposes of these rules, “radiobioassay” is an equivalent term.

  • Opioid antagonist means a drug that binds to opioid

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Licensed Compound means a TAK-385 Licensed Compound or a TAK-448 Licensed Compound.

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Therapeutic school means a residential group living facility:

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Vaccine means a specially prepared antigen which, upon administration to a person, will result in immunity and, specifically for the purposes of this rule, shall mean influenza and pneumococcal vaccines.

  • Collaboration Product means any pharmaceutical product in finished form that contains a Collaboration Compound, either as the sole active ingredient or in combination with one or more other active ingredients, and all present and future formulations, dosages and dosage forms thereof.

  • Cannabinoid means any of the chemical compounds that are the active constituents of marijuana.

  • ISIS means the department’s individualized services information system.

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • haemophilia means an inheritable disease, usually affecting only male but transmitted by women to their male children, characterised by loss or impairment of the normal clotting ability of blood so that a minor would may result in fatal bleeding;

  • Merck has the meaning set forth in the preamble.

  • Marihuana-infused product means a topical formulation, tincture, beverage, edible substance, or similar product containing marihuana and other ingredients and that is intended for human consumption.

  • Nicotine product means the same as that term is defined in Section 76-10-101.

  • Collaborating physician means the physician who,